Home / Themes / MedTech Short '25: Vaccine Makers
MedTech Short '25: Vaccine Makers (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 1 with notes · 4 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis short basket targets vaccine-focused companies facing demand erosion, policy deprioritization, and declining funding as the political and healthcare focus
Thesis
This short basket targets vaccine-focused companies facing demand erosion, policy deprioritization, and declining funding as the political and healthcare focus under Trump 2.0 shifts away from infectious disease and toward chronic disease management. With RFK Jr. leading HHS and public pandemic fatigue, the environment is deeply unfavorable for vaccine pipeline monetization, public-private contracts, and valuation premiums.
Bull case
RFK Policy Drag on Infectious Disease: Trump's health agenda, shaped by RFK Jr., deprioritizes infectious diseases in favor of chronic disease treatment, shrinking vaccine funding and NIH/NIAID support
End of Pandemic-Era Spending: U.S. and global stockpiles have normalized, and contracts for COVID-related vaccines have wound down. Companies like MRNA and NVAX are left with excess capacity and dwindling demand
Anti-Vax Sentiment + Budget Austerity: RFK's credibility with anti-vaccine constituencies and Trump's broader deficit-reduction agenda create reputational and budgetary headwinds for new vaccines, especially those targeting low-incidence diseases
Bear case
Infectious Disease Resurgence: A surprise outbreak (e.g., flu variant, avian influenza, or RSV spike) could reignite interest in broad vaccine programs and restore some near-term contract momentum for vaccine makers.
Global Ex-U.S. Demand Recovery: Europe, Asia, or emerging markets may expand immunization programs with new platform vaccines (e.g., PCVX pneumococcal or MRNA oncology), supporting revenue growth outside U.S. politics.
Pipeline Breakthroughs in Non-COVID Areas: Positive Phase 2/3 data in respiratory or endemic vaccines (e.g., RSV, HIV, or universal flu from MRNA or GILD) could shift investor narrative toward long-term optionality over political headwinds.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Federal Vaccine Procurement and Budget Allocations | Annual / Updates | Tracks funding flow to vaccines; a decline supports thesis of deprioritization. | Google_Sheets |
| Vaccine Administration Volume (COVID, RSV, Flu, etc.) | Weekly / Monthly | Direct demand signal; lower shots per capita confirms fading relevance. | Google_Sheets |
| Global Vaccine Trial Progress and Pipeline Catalysts | Rolling / Monthly | Measures pipeline traction and risk of narrative reversal via clinical success. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| PFE_0a01f9d3 | later this year at a conference | 2026-09-01 | 2026-12-31 | Presentation of the full data set from the TRANQUILLO 1 and 2 studies for Litfulo in nonsegmental vitiligo. | The full data presentation will provide comprehensive insights into Litfulo's clinically meaningful and statistical efficacy, reinforcing its potential in the vitiligo market. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
| PFE_a3b83d3f | this year | 2026-09-01 | 2026-12-31 | Start of a pivotal trial investigating NURTEC's use as a treatment for chronic migraine. | This pivotal trial initiation aims to expand NURTEC's label, further strengthening Pfizer's leadership in providing treatment options for migraine patients. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
| PFE_a1fcc382 | later this year | 2026-09-01 | 2026-12-31 | Release of the clinical trial design for the adjuvant study of atirmociclib in ER-positive breast cancer. | This milestone is crucial for advancing atirmociclib, which is believed to be highly differentiated in the early adjuvant setting due to its tolerability profile, representing a significant opportunity. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
| PFE_fe771000 | fourth quarter | 2026-10-01 | 2026-12-31 | First readout of the MEVPRO-1 Phase III study for mevrometostat in post-abiraterone metastatic hormone-resistant prostate cancer. | This pivotal study readout could establish mevrometostat as a breakthrough therapy, delaying resistance to XTANDI and representing a 100% global commercial opportunity for Pfizer. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
Constituents
- PFET3— Pfizer Inc.
- GILDT3· no notes yet
- MRNAT3· no notes yet
- NVAXT3· no notes yet
- PCVXT3· no notes yet